Scleroderma and Lupus Health Study Claims No Environmental Link To Disease PDF Print E-mail
Friday, 08 January 2010 22:09
taken from http://www.flickr.com/photos/h_de_c/3291978657/ via creative commonsThe Massachusetts Department of Public Health (DPH) has released the results of an investigation into the occurrence of scleroderma and lupus, two rare chronic diseases, in South Boston. The investigation found that the prevalence of scleroderma was indeed statistically significantly higher than expected among Caucasian females. No specific associations with environmental exposures were identified.

The study did confirm that a previous diagnosis of rheumatoid arthritis was associated with scleroderma and lupus among current and former South Boston residents. Further, the study also found that a family history of specific rheumatic diseases was significantly associated with a diagnosis of scleroderma and lupus.

The Department of Public Health's study was initiated in 1998, as a result of concerns raised by the South Boston community and then-State Senator Stephen F. Lynch, who now represents Massachusetts' 9th congressional district. At that time, the community expressed concerns about a perceived increase in the number of women who had grown up in South Boston and were later diagnosed with scleroderma. Community members also expressed concern about possible environmental exposure.

"The release of this study represents more than ten years of collaboration between the Massachusetts Department of Public Health and the South Boston community to address concerns of the prevalence of scleroderma and lupus," Congressman Stephen F. Lynch said. "I am pleased to see that this study has been completed and the results will guide future research and help those living with these chronic diseases."

DPH Commissioner John Auerbach added, "These types of studies are important and enhance our collaboration with community partners to improve public health."

DPH responded to the communities’ concerns by collaborating with clinical researchers and epidemiologists at Boston Medical Center, Tufts Medical Center and the South Boston Community Health Center to conduct a retrospective case-control study to investigate the occurrences of both diseases and to identify possible contributing factors (environmental and non-environmental) among individuals with scleroderma and lupus. In addition, DPH established a South Boston Community Advisory Committee to facilitate community outreach and ongoing communication.

Study participants were interviewed about their residential, occupational, medical, family and reproductive histories, as well as hobbies and recreational activities in the area. The study also investigated possible historical exposures to a number of sources of environmental pollution, as well as spatial and temporal (time) patterns among current and former residents with these diseases.

Source: Office of Health and Human Services (EOHHS)

If you're logged in, you can download a copy of the report, presentation, and questions and answers below.

 
More articles :

» Optical Coherence Tomography: The first Quantitative Imaging Biomarker for Scleroderma

Using the , manufactured in the UK by Michelson Diagnostics Ltd, scientists at the Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds have developed the first quantitative imaging biomarker for skin involvement in . Scleroderma...

» Our First Year Anniversary

Celebrating an important anniversary is always a blessing. The Scleroderma Care Foundation was officially incorporated on 15th October 2008. Its mission to provide support and education for persons afflicted with within Trinidad and Tobago became a...

» Curcumin May Have Therapeutic Value In Treating Scleroderma

Turmeric, a shrub related to ginger, is grown throughout India, other parts of Asia, and Africa. It is well known for its warm, bitter taste and golden yellow color. Turmeric is commonly used in fabric dyes and foods such as curry powders, mustards,...

» Testing New Drugs for Early Diffuse Systemic Sclerosis

For patients with the connective tissue disease known as Systemic Sclerosis or – there are few reliable drug treatments. There has been emerging interest in the potential of a class of drugs called (TKI) to ameliorate a major feature of the...

» How To Know If Your Body Is Acidic?

It can be really crucial to remember that the are normally based on the quantity of acids we have in our body. These signs and symptoms are grouped according to it order of severity. Much less severe symptoms may well indicate that you simply are...

» Scleroderma Foundation Medical Advisory Board Offers Consensus On Gleevec

® (imatinib mesylate, Novartis) is approved in the United States for the treatment of certain forms leukemias and solid tumors. The recent discovery that Gleevec® inhibits important cellular enzymes that control fibrosis led to studies to evaluate...